Next Generation Bispecifics in Solid Tumors

In this podcast, you will hear a panel discussion moderated by Dr Priti Hegde, Foundation Medicine, from the 2020 IO360° Summit regarding next generation bispecifics in solid tumors. Discussion questions include:

• What is happening in hematology bispecific programs compared to solid tumor bispecific programs?
• What do bispecifics look like in solid tumors and what is driving efficacy?
• What’s hindering efficacy in solid tumors compared to hematology?
• How can we improve on it?
• What should we be doing on the next generation bispecifics?

Panelists:
Julie Bailis, PhD, Amgen
Dimitris Skokos, PhD, Regeneron Pharmaceuticals
David Schaer, PhD, Pfizer
Pablo Umaña, PhD, Roche

To learn more about the 2021 IO360° Summit, please visit www.io360summit.com